Study of the electrophysiological mechanisms of anticonvulsant action of the original levetiracetam analog the compound GIZH-290
https://doi.org/10.37489/2587-7836-2021-1-38-44
Abstract
The study used the method of cobalt epilepsy, which allows rats with long-term implanted electrodes in the cortical and subcortical structures of the brain to monitor the dynamics of the formation and migration of Epi-foci for a long time. It was found that in the control at the 1st stage of development of the Epi system, Epi activity is most pronounced in the electrocorticograms of the ipsilateral cortex, and at the 2nd, stable stage of development of the Epi system – in the contralateral cortex and subcortical structures. The compound GIZH-290 (the original structural analogue of levetiracetam) reduces the number of Epi discharges and their duration at the 2nd, stable stage of the development of the Epi system. The target structure of the GIZH – 290 compound was the hippocampus. The compound GIZH -290 selectively statistically significantly reduces both the number and duration of Epi – discharges only in the hippocampus and does not affect the foci of epileptic activity in the ipsi-and contralateral cortex and hypothalamus.
Keywords
About the Authors
T. A. Voronina
FSBI «Zakusov Institute of Pharmacology»
Russian Federation
Russian Federation
Voronina Tatiana A., Dr. Sci. (Med.), professor, Head of the Laboratory of Psychopharmacology
Moscow
S. A. Litvinova
FSBI «Zakusov Institute of Pharmacology»
Russian Federation
Russian Federation
Litvinova Svetlana A., PhD in Biological Sci., leading researcher Laboratory of Psychopharmacology
Moscow
N. A. Gladysheva
FSBI «Zakusov Institute of Pharmacology»
Russian Federation
Russian Federation
Gladysheva Natalia A., Laboratory assistant researcher of the Laboratory of Psychopharmacology
Moscow
А. A. Yakovleva
FSBI «Zakusov Institute of Pharmacology»
Russian Federation
Russian Federation
Yakovleva Alla A., Laboratory assistant researcher of the Laboratory of Psychopharmacology
Moscow
References
1. Карлов В.А. Эпилепсия у детей и взрослых женщин и мужчин: руководство для врачей. – М.: Медицина; 2019. – 893 С. [Karlov VA. Epilepsy in children and adult women and men: a guide for doctors. Moscow: Medicine; 2019. (In Russ).]
2. Авакян Г.Н., Воронина Т.А., Хромых Е.А. Эпилепсии. Патогенез. Патогенетическая терапия. Пособие для врачей. – М.: 2007. – 148 С. [Avakyan GN, Voronina TA, Khromykh EA. Epilepsii. Patogenez. Patogeneticheskaya terapiya. Posobie dlya vrachei. Moscow: 2007. (In Russ).]
3. ВОЗ World Healt Organization. International Classification of Functioning Disability and Healt. 2017.
4. Hauser WF. The descriptive epidemiology of epilepsy. Epilepsy: translational, clinical and social aspects. Proceeding of the conference Moscow. 2013;83–117.
5. Wolf P. Nosology of the epilepsies and its reflection in classification. Comprehensive Epileptology. Proceeding of the conference Saint Petersburg. 2011;181–189
6. Kwan P, Brodie MJ. Refractory epilepsy: mechanisms and solutions. Expert Rev Neurother. 2006;6(3):397–406. DOI: 10.1586/14737175.6.3.397.
7. De Smedt T, Raedt R, Vonck K, Boon P. Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug. CNS Drug Rev. 2007;13(1):57–78. DOI: 10.1111/j.1527-3458.2007.00005.x.
8. Mohanraj R, Parker PG, Stephen LJ, Brodie MJ. Levetiracetam in refractory epilepsy: a prospective obsevational study. Seizure. 2005;14(1):23–27. DOI: 10.1016/j.seizure.2004.02.006.
9. Ковалев И.Г., Воронина Т.А., Литвинова С.А., Жмуренко Л.А., Мокров Г.В. Сравнение противосудорожных и мнемотропных свойств новых производных 4-фенилпирролидона, леветирацетама и пирацетама. Экспериментальная и клиническая фармакология, 2017;80(6):13–18. [Kovalev IG, Voronina TA, Litvinova SA, Zhmurenko LA, Mokrov GV. Comparison of the anticonvulsant and mnemotropic properties of new derivatives of 4-phenylpyrrolidone, Levetiracetam, and Piracetam in outbred mice and rats. Experimental and Clinical Pharmacology. 2017;80(6):13–18. (In Russ).] DOI: 10.30906/0869-2092-2017-80-6-13-18
10. Крыжановский Г.Н. Детерминантные структуры в патологии нервной системы. – М.: Медицина; 1980, 359 С. [Kryzhanovsky GN. Determinantnye struktury v patologii nervnoj sistemy. Moscow: Medicine; 1980. (In Russ).]
11. Крыжановский Г.Н. Дисрегуляционная патология. – М.: Медицина; 2002, 247 С. [Kryzhanovsky GN. Disregulyacionnaya patologiya. Moscow: Medicine; 1980. (In Russ).]
12. Неробкова Л.Н., Авакян Г.Г., Воронина Т.А., Авакян Г.Н. Клиническая электроэнцефалография. Фармакоэлектроэнцефалография. – М.: ГЭОТАР-Медиа; 2020. – 288 с. (Серия «Библиотека врача-специалиста»). [Nerobkova LN, Avakyan GG, Voronina TA, Avakyan GN. Klinicheskaya elektroencefalografiya. Farmakoelektroencefalografiya. Moscow: GEOTAR-Media; 2020. (In Russ).]
13. Воронина Т.А., Авакян Г.Г., Неробкова Л.Н., Литвинова С.А., Авакян Г.Н. Новые биомолекулярные мишени для создания противоэпилептических препаратов. Эпилепсия и пароксизмальные состояния. 2015;7(4):59-65. [Voronina TA., Avakyan GG, Nerobkova LN, Litvinova SA, Avakyan GN. New biomolecular targets for antiepileptic drugs. Epilepsy and Paroxysmal conditions. 2015;7(4):59–65. (In Russ).]. DOI: 10.17749/2077-8333.2015.7.4.059-065
14. Lason W, Chlebicka M, Rejdak K. Research advances in basic mechanisms of seizures and antiepileptic drug action. Pharmacol Rep. 2013;65(4):787–801. DOI: 10.1016/s1734–1140(13)71060-0.
15. Литвинова С.А., Воронина Т.А., Неробкова Л.Н., Кутепова И.С., Авакян Г.Г., Авакян Г.Н. Особенности действия леветинола на развитие судорожной активности у крыс с кобальт-индуцированной хронической эпилепсией. Эпилепсия и пароксизмальные состояния. 2018;10(1):52–62. [Litvinova SA, Voronina TA, Nerobkova LN, Kutepova IS, Avakyan GG, Avakyan GN. Effects of levetinol on epileptiform activity of the brain in rats with cobalt-induced epilepsy. Epilepsy and paroxysmal conditions. 2018;10(1):52–62. (In Russ).]. DOI: 10.17749/2077-8333.2018.10.1.052-062
16. Litvinova Svetlana, Voroninа Tatyana, Nerobkova Lubov, Kutepova Inga, Avakyan Georgii, and Avakyan Gagik. Levetiracetam effect and electrophysiological mechanism of action in rats with cobalt-induced chronic epilepsy. Eur J Pharmacol. 2019;854:380–386. DOI: 10.1016/j.ejphar.2019.04.041.
17. Авакян Г.Н., Неробкова Л.Н., Воронина Т.А., Маркина Н.В. Митрофанов А.А. Влияние карбамазепина на структурно-функциональные связи в развитии эпилептической системы. Экспериментальная и клиническая фармакология. 2002;65(2):7–10. [Avakyan GN, Nerobkova LN, Voronina TA, Markina NV, Mitrofanov AA. The effect of carbamazepine on structural and functional connections in the development of the epileptic system. Experimental and Clinical Pharmacology. 2002;65(2):7–10. (In Russ).]
18. Воронина Т.А., Стойко М.И., Неробкова Л.Н., Авакян Г.Н., Крайнева В.А. Анализ влияния фенитоина на распространение судорог и эпилептический статус, вызванный нейротоксином гомоцистеином тиалактоном у крыс с кобальтовой эпилепсией. Экспериментальная и клиническая фармакология. 2003;66(1):5–8. [Voronina TA, Stoiko MI, Nerobkova LN, Avakyan GN, Kraineva VA. Analysis of the effect of phenytoin on the spread of seizures epileptic status caused by the neurotoxin homocysteine thialactone in rats with cobalt epilepsy. Experimental and Clinical Pharmacology. 2003;66(1):5–8. DOI: 10.30906/0869-2092-2002-65-1-15-18
19. Bregman B, F Le Saux, Trottier S, Chauvel P, Maurin Y. Chronic Cobalt-induced Epilepsy: Noradrenaline Ionophoresis and Adrenoceptor Binding Studies in the Rat Cerebral Cortex. J Neural Transm. 1985;63(2): 109–118. DOI: 10.1007/BF01252611.
20. Hyon Mee Chun, Jae Moon Kim1, Young Ho Lee. Pattern of Hippocampal Cell Changes in Cobalt / Homocysteine induced Status Epilepticus. The Korean J. Anat. 2002;35(1): 37–42.
21. Walton NY, Jaing Q, Hyun B, Treiman DM. Lamotrigine vs. phenytoin for treatment of status epilepticus: comparison in an experimental model. Epilepsy Res. 1996;24(1):19–28. DOI: 0.1016/0920-1211(96)00007-1.
22. Воронина Т.А., Неробкова Л.Н. Методические рекомендации по доклиническому изучению противосудорожной активности лекарственных средств. Руководство по проведению доклинических исследований лекарственных средств. – М.: Гриф и К; 2012; Часть 1. Глава 14: С.235-350. [Voronina TA, Nerobkova LN. Guidelines for the preclinical study of anticonvulsant activity of drugs. Guidelines for preclinical studies of drugs. Moscow: Grif I K; 2012; Part 1. Chapter 14: p. 235–350 (In Russ).]
23. Виноградова О.С. Гиппокамп и память. – М.: Наука; 1975, 388 С. [Vinogradova OS. Gippokamp i pamyat'. Nauka. 1975. (In Russ).]
24. Broadbent NJ, Squire LR, Clark RE. Spatial memory, recognition memory, and the hippocampus. Proc Natl Acad Sci USA. 2004; 101(40):14515– 14120. DOI: 10.1073/pnas.0406344101.
25. Mizuno K, Giese K.P. Hippocampus-dependent memory formation: do memory type-specific mechanisms exist? J Pharmacol Sci. 2005;98(3): 191–197. DOI: 10.1254/jphs.crj05005x.
26. Fernández-Ruiz A, Oliva A, Fermino de Oliveira E, Rocha-Almeida F, Tingley D, Buzsáki G. Long-duration hippocampal sharp wave ripples improve memory. Science. 2019;364(6445)61082–1086. DOI: 10.1126/science.aax0758.
Review
For citations:
Voronina T.A., Litvinova S.A., Gladysheva N.A., Yakovleva А.A. Study of the electrophysiological mechanisms of anticonvulsant action of the original levetiracetam analog the compound GIZH-290. Pharmacokinetics and Pharmacodynamics. 2021;(1):38-44. (In Russ.) https://doi.org/10.37489/2587-7836-2021-1-38-44
Views:
666
Email this article 